Pertuzumab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) m Use INN; wikilink |
Anypodetos (talk | contribs) Added mab_type, updated source |
||
| Line 2: | Line 2: | ||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| |
| mab_type = mab |
||
| source = zu/o |
|||
| target = [[HER2]] |
| target = [[HER2]] |
||
| CAS_number = 380610-27-5 |
| CAS_number = 380610-27-5 |
||
| Line 35: | Line 36: | ||
{{Humanizedmonoclonals}} |
{{Humanizedmonoclonals}} |
||
{{ |
{{monoclonal-antibody-stub}} |
||
[[Category:Monoclonal antibodies]] |
[[Category:Monoclonal antibodies]] |
||
Revision as of 19:46, 4 April 2010
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
Pertuzumab (also called 2C4, trade name Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Pertuzumab is currently being developed by Genentech.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[3]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ de Bono, Johann S. (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
- ^ Genentech press release - May 15, 2005
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |